🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.1636
-0.0230 (-12.33%)
At close: Nov 20, 2026, 4:00 PM EST
0.1666
+0.0030 (1.83%)
After-hours: Nov 20, 2026, 7:46 PM EST

Vistagen Therapeutics Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
2.381.270.491.06-0.231.11
Revenue Growth
230.24%161.11%-54.32%--1.78%
Gross Profit
2.381.270.491.06-0.231.11
Selling, General & Admin
18.1918.4217.0814.0614.6613.96
Research & Development
44.7454.9739.3820.0244.3834.92
Operating Expenses
62.9373.456.4634.0959.0448.89
Operating Income
-60.55-72.13-55.97-33.02-59.27-47.78
Interest & Investment Income
1.612.444.563.350.030.02
Other Non Operating Income (Expenses)
00.010.010.31--
EBT Excluding Unusual Items
-58.94-69.68-51.41-29.36-59.24-47.76
Pretax Income
-58.94-69.68-51.41-29.36-59.24-47.76
Income Tax Expense
0.010.010.0100.010
Net Income
-58.94-69.69-51.42-29.36-59.25-47.76
Preferred Dividends & Other Adjustments
-----0.95
Net Income to Common
-58.94-69.69-51.42-29.36-59.25-48.71
Net Income Growth
------
Shares Outstanding (Basic)
4338311977
Shares Outstanding (Diluted)
4338311977
Shares Change
32.35%23.31%59.53%178.13%5.45%129.85%
EPS (Basic)
-1.37-1.83-1.67-1.52-8.51-7.38
EPS (Diluted)
-1.37-1.83-1.67-1.52-8.51-7.38
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-60.73-66.59-42.29-25.87-49.93-45.46
Free Cash Flow Per Share
-1.41-1.75-1.37-1.34-7.17-6.89
Gross Margin
100.00%100.00%100.00%100.00%-100.00%
Operating Margin
-2543.13%-5683.69%-11517.08%-3103.48%--4308.68%
Profit Margin
-2475.56%-5491.33%-10579.83%-2759.59%--4392.42%
Free Cash Flow Margin
-2550.48%-5247.20%-8701.24%-2431.77%--4099.28%
EBITDA
-60.34-71.93-55.82-32.89-59.14-47.63
D&A For EBITDA
0.210.20.150.130.130.15
EBIT
-60.55-72.13-55.97-33.02-59.27-47.78
Revenue as Reported
2.381.270.491.06-0.231.11
SEC Filings: 10-K · 10-Q